Oppenheimer & Co. Inc. Grows Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Oppenheimer & Co. Inc. increased its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) by 25.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,408 shares of the biotechnology company’s stock after buying an additional 13,762 shares during the period. Oppenheimer & Co. Inc.’s holdings in Capricor Therapeutics were worth $1,040,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CAPR. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics in the 1st quarter worth about $40,000. Main Street Financial Solutions LLC raised its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC acquired a new position in Capricor Therapeutics in the 3rd quarter valued at about $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the 2nd quarter valued at about $147,000. Finally, Bank of New York Mellon Corp raised its stake in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CAPR. Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald boosted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Finally, Maxim Group upped their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Insider Buying and Selling

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 12.00% of the company’s stock.

Capricor Therapeutics Stock Performance

CAPR opened at $18.38 on Tuesday. The firm has a 50 day moving average price of $15.21 and a 200 day moving average price of $8.50. The company has a market cap of $834.56 million, a PE ratio of -17.34 and a beta of 4.00. Capricor Therapeutics Inc has a 1 year low of $2.87 and a 1 year high of $23.40.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.